Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea in obese adults ...

Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.

The U.S. Food and Drug Administration (FDA) has approved Zepbound, a prescription weight-loss medication, as the first drug ...

This time last year, people were still bickering about whether Novo Nordisk's Wegovy and Eli Lilly & Co.'s Zepbound represented a shortcut to losing weight or a medical breakthrough. But with reams of ...

Tirzepatide is the active ingredient in Eli Lilly's Zepbound for obesity and Mounjaro ... because the FDA just approved ...

The FDA on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug ...

An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...